Azathioprine-induced fatal macrocytic anemia in rabbits

Polish Journal of Pharmacology

Volumn 54, Issue 5, 2002, Pages 513-516

  Al Safi, Saafan ^a   Tashtoush, Bassam ^a   Abdul Razzak, Khalid ^a  

^a Department of Clinical Pharmacy ^*  (Jordan)

Author keywords

Azathiorprine; Erythrocytes; Leucocytes; Macrocytic anemia; Platelets; Thrombocytosis

Indexed keywords

AZATHIOPRINE; DRUG SOLVENT; HEMOGLOBIN; SODIUM CHLORIDE; SODIUM HYDROXIDE; IMMUNOSUPPRESSIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD CELL COUNT; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FATALITY; LEUKOCYTE COUNT; MACROCYTIC ANEMIA; NONHUMAN; RABBIT; THROMBOCYTOSIS; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; ERYTHROCYTE COUNT; MORTALITY; THROMBOCYTE COUNT;

ANEMIA, MACROCYTIC; ANIMALS; AZATHIOPRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTE COUNT; HEMOGLOBINS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; PLATELET COUNT; RABBITS;

EID: 0036403313     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Abu-Shakra M., Shenfeld Y.: Azathioprine therapy for patients with systemic lupus erythematosus. Lupus, 2001, 10, 152-153.
2. Beale K.M., Altman D., Clemmons R.R., Bolon B.: Systemic toxicosis associated with azathioprine administration in domestic cats. Amer. J. Vet. Res., 1992, 53, 1236-1240.
3. Bergan S., Rugstad H.E., Bentdal O., Sodal G., Hartman A., Leivestad T., Stokke O.: Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. Transplantation, 1998, 66, 334-339.
4. Black A.J., Mcleod H.L., Capell H.A., Powrie R.H., Matwe L.K., Pritchard S.C., Collie-Duguid E.S., Reid D.M.: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med., 1998, 129, 716-718.
5. Bottiger L.E., Rausing A.: Pure red cell anemia. Ann. Intern. Med., 1972, 76, 593-597.
6. Bouhnik Y., Lemann M., Mary J.Y., Scemama G., Tai R., Matuchansky C., Modigliani R., Rambaud J.C.: Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet, 1996, 347, 215-219.
7. Cheesbrough M., Mcarthur J.: A Lab Manual for Rural Tropical Hospitals, Churchill Livingstone, London, 1976.
8. Chocair P.R., Bulbol W.S., Sabbaga E.: Macrocytosis after renal transplantation. Rev. Hosp. Clin. Fac. Med. Sao Paulo, 1982, 37, 179-182.
9. Chocair P.R., Duley J.A., Simmonds H.A., Cameron J.S.: The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation, 1992, 53, 1051-1056.
10. Cornell W.R., Kamm M.A., Ritchie J.K., Lennard-Jones J.E.: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut, 1993, 34, 1081-1085.
11. Creemers G.J., van Boven W.P.L., Lowenberg B., van der Heul C.: Azathioprine-associated pure red cell aplasia. J. Intern. Med., 1993, 233, 85-87.
12. Declerk Y.A., Ettenger R.B., Orlega J.A., Pennisi A.J.: Macrocytosis and pure RBC anemia caused by azathioprine. Amer. J. Dis. Child., 1980, 134, 377-379.
13. Dominguez O.J., Robledo T., Matinez-Cocera C., Alonso A., Cimarra M., Chamorro M., Plaza A.: Desensitization to azathioprine. J. Invest. Allerg. Clin. Immunol., 1999, 9, 337-338.
14. Ellion G.B., Callahan S.W., Bieber S., Hitchings G.H., Rundles R.W.: A summary of investigations with 6-{1'-methyl-4'-nitro-5'-imidazolyl}thiopurine. Cancer Chemother. Rep., 1961, 14, 93-98.
15. Fraser G., Orchard T.R., Jewell D.P.: The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut, 2002, 50, 485-489.
16. Gabriel S.E., Coyle D., Moreland L.W.: A clinical and economic review of disease-modifying antirheumatic drugs. Pharmacoeconomics, 2001, 19, 715-728.
17. Gaffney K., Scott D.G.: Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. Brit. J. Rheumatol., 1998, 37, 824-836.
18. Kader H.A., Wenner W.J., Telega, G.W., Maller E.S., Baldassano R.N.: Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity. J. Clin. Gastroenterol., 2000, 30, 409-413.
19. Kerstens P.J., Stolk J.N., de Abru R.A., Lambooy L.H., van de Putt L.B., Boerbooms A.A.: Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum., 1995, 38, 142-145.
20. Kim C.J., Park K.I., Inoue H., Yoshida T., Yoshiki T., Tomoyoshi T., Abe H., Kodama M., Sako H., Nakane Y.: Azathioprine-induced megaloblastic anaemia with pancytopenia 22 years after living-related renal transplantation. Int. J. Urol., 1998, 5, 100-102.
21. Klippel J.H., Decker J.L.: Relative macrocyosis in cyclophosphamide and azathioprine therapy. JAMA, 1974, 229, 180-181.
22. Lamers C.B., Griffioen G., Van Hogezand R.A., Veenendaal R.A.: Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand. J. Gastroenterol. Suppl., 1999, 230, 111-115.
23. Louis E., Belaiche J.: Treatment of inflammatory bowel disease with azathioprine: how to use it in 1999. Acta Gastroenterol. Belg., 1999, 62, 437-439.
24. MacPhee I.A., Bradley J.A., Briggs J.D., Junor B.J., MacPherson S.G., Mcmillan M.A., Rodger R.S., Watson M.A.: Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation, 1998, 66, 1186-1192.
25. Marion J.F.: Toxicity of 6-mercaptopurine/azathioprine in patients with inflammatory bowel disease. Inflamm. Bowel Dis., 1998, 4, 116-117.
26. McErath B.P., Ibels L.S., Raik E., Hargrave M.J.: Erythroid toxicity of azathioprine. Macrocytosis and selective bone marrow hypoplasis. Quart. J. Med., 1975, 44, 57-63.
27. Meggitt S.J., Reynolds N.J.: Aazathioprine for atopic dermatitis. Clin. Exp. Dermatol., 2001, 26, 369-375.
28. Nicholis A.J., Davidson R.J.: Development of macrocytosis during azathioprine therapy after renal transplantation. A correlation of renal function with MCV. Transplantation, 1979, 27, 220-221.
29. Old C.W., Flannery E.P., Grogan I.M.: Azathioprine induced pure red cell aplasia. JAMA, 1978, 240, 552-556.
30. Pearson D.C., May G.R., Fick G.H., Sutherland L.R.: Azathioprine and 6-mercaptopurine in Crohn's disease. Ann. Intern. Med., 1995, 122, 132-142.
31. Proctor S.J., Walker W., Rai C.: Imuran-induced macrocytosis and splenectomy following renal transplantation. Transplantation, 1976, 22, 404-406.
32. Scerri L.: Azathioprine in dermatological practice. An overview with special emphasis on its use in nonbullous inflammatory dermatoses. Adv. Exp. Med. Biol., 1999, 455, 343-348.
33. Schmidt P., Kopsa H., Pils P., Zazgonik J., Deutsch E.: Macrocytosis in renal transplant patients. Wien. Klin. Wochenschr., 1976, 88, 532-535.
34. Shoker A.S.: Immunopharmacologic therapy in renal transplantation. Pharmacotherapy, 1996, 16, 562-575.
35. Snow J.L., Gibson L.E.: A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J. Amer. Acad. Dermatol., 1995, 32, 114-116.
36. Stolk J.N., Boerbooms A.M., de Abreu R.A., de Koning D.G., van Beusekom H.J., Muller W.H., van de Putte L.B.: Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum., 1998, 41, 1858-1866.
37. Tavadia S.M., Mydlarski P.R., Reis M.D., Mittmann N., Pinkerton P.H., Shear N., Sauder D.N.: Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J. Amer. Acad. Dermatol., 2000, 42, 628-632.
38. Wickramasinghe S.N., Dodsworth H., Rault R.M., Hulme B.: Observations on the incidence and cause of macrocytosis in patients on azathioprine therapy following renal transplantation. Transplantation, 1974, 18, 443-446.
39. Yoran B., Lemann M., Mar J.Y., Scemama G., Tai R., Matuchansky C., Modigliani R., Rambaud J.C.: Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet, 1996, 347, 215-219.
40. Zazgornik J.: Azathioprine induced macrocytosis and red cell aplasia in renal transplant patients. Nephrol. Dialysis Transplant., 1997, 12, 628.